Amyloidosis Cardiac
21
11
11
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
10%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (21)
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
BE.Amycon Biobank & Data Registry UZ Leuven
Multimodal Analysis of Endomyocardial Biopsies
ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers
Multimodality Cardiac Imaging for Disease Progression in ATTR-CM
Ultrasound Therapy In Cardiac Amyloidosis
Essen Amyloidosis Registry
Intracardiac Flow Assessment in Cardiac Amyloidosis
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
Cardiac Amyloidosis in HFpEF
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
Amyloidosis Incidence in High-Risk Cardiac Device Patients
Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment
The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
ATTR Amyloidosis in Elderly Patients With Aortic Stenosis
Cardiac Contractility Modulation Therapy in Amyloid Cardiomyopathy Patients With Heart Failure
Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel Syndrome
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy